Jefferies reiterates NPS at buy, $16 target

NPS Pharmaceuticals Inc. was reiterated by Jefferies & Co. Inc. analyst Adam Walsh at a buy rating with a $16 price target as the company expects to approve Preos for vertebral fractures in the first quarter of 2006. The company reported a third-quarter loss of $0.95 per share versus Jefferies' estimate of $1.13 and consensus of $1.17. The upside was primarily due to increased revenue resulting from higher sales of Sensipar and a step-up in royalty rate due to the achievement of set cumulative annual sales thresholds, Jefferies said. Jefferies recommends investors build or add to NPS positions ahead of the expected Preos approval. Shares of the Salt Lake City drug discovery company were up $0.40, or 3.98%, at $10.44 on volume of 969,637 shares versus the three-month running average of 530,436 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.